Alembic Pharmaceuticals Reports Q4 FY26 Results: Revenue Up 4%, Net Profit Gains 29%
Alembic Pharmaceuticals Limited announced its consolidated financial results for the fourth quarter and fiscal year ended March 31, 2026. The company reported robust performance, noting a 4% year-over-year increase in revenue from operations and a 29% year-over-year jump in profit after tax.For the fourth quarter alone (Q4 FY26), the company saw revenue from operations increase by 4% year-over-year, reaching Rs. 1,848 Cr. Profit After Tax stood at Rs. 203 Cr, reflecting a 29% year-over-year increase. Furthermore, EBITDA pre R&D grew by 8% year-over-year to Rs. 455 Cr, maintaining a pre-R&D EBITDA margin of 25%.
Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, commented that Q4 FY26 reflects disciplined execution across all business units. He stated that the focus on profitability, operational delivery, and long-term growth investments drove the growth. He highlighted that the company began its journey in the US Branded Business with the launch of Pivya, establishing a new avenue for long-term value creation.
Operational Highlights and Market Expansion
The International Business segment reported significant growth, with the US Formulation growing by 11% to Rs. 564 Cr. During the quarter, the company executed six launches in the US market and received four ANDA approvals. Ex-US Generics recorded revenue of Rs. 369 Cr.Domestically, the India Branded Business showed encouraging performance, posting 4% year-over-year growth and achieving Rs 568 Cr in revenue for the quarter. Segments such as Gynaecology, Gastrology, Ophthalmology, and Animal Healthcare were key contributors to the quarter's performance. Additionally, two new products were introduced into the Indian market during the period.
US Branded Portfolio Launch
The company marked a significant strategic step into the US branded pharmaceuticals market through Alembic Therapeutics, its step-down wholly owned subsidiary. The launch of Pivya marked the start of Alembic's strategy to build a specialized branded portfolio in the US. Pivya is noted as a first-line oral antibiotic option for treating uncomplicated urinary tract infections (uUTIs) in women.Financial Performance Summary
The performance data for Formulation, USA, Ex-US, and API business segments is summarized below:| Particulars | Q4 FY25 (Rs in Cr.) | Q4 FY26 (Rs in Cr.) | % Change | FY25 (Rs in Cr.) | FY26 (Rs in Cr.) | % Change |
|---|---|---|---|---|---|---|
| Formulation | ||||||
| India | 545 | 568 | 4% | 2339 | 2458 | 5% |
| USA | 508 | 564 | 11% | 1957 | 2206 | 13% |
| Ex-US | 375 | 369 | -2% | 1243 | 1494 | 20% |
| API | 342 | 347 | 2% | 1133 | 1187 | 5% |
| Total | 1,770 | 1,848 | 4% | 6,672 | 7,345 | 10% |
The API business saw a 2% increase in revenue, reaching Rs. 347 Cr. Overall, the revenue growth across the key segments underpinned the total revenue growth reported for the year.
APLLTD Stock Price Movement
Shares of Alembic Pharmaceuticals Limited today slipped by 0.01% to settle at ₹785.65 in after-hours trading. The stock experienced substantial activity on the exchange, reporting a total volume of 327,819 shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.